scholarly journals Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour

2016 ◽  
Vol 61 ◽  
pp. 94-101 ◽  
Author(s):  
Andrew J. Wagner ◽  
Mark Agulnik ◽  
Michael C. Heinrich ◽  
Daruka Mahadevan ◽  
Richard F. Riedel ◽  
...  
Keyword(s):  
Dose Escalation ◽  
Second Generation ◽  
Gastrointestinal Stromal Tumour ◽  
Hsp90 Inhibitor ◽  
Stromal Tumour ◽  
Dose Escalation Study

scholarly journals First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

2014 ◽  
Vol 21 (1) ◽  
pp. 87-97 ◽  
Author(s):  
Geoffrey I. Shapiro ◽  
Eunice Kwak ◽  
Bruce J. Dezube ◽  
Murray Yule ◽  
John Ayrton ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Second Generation ◽  
Hsp90 Inhibitor ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3083-3083 ◽  
Author(s):  
J. M. Cleary ◽  
E. I. Heath ◽  
E. L. Kwak ◽  
B. J. Dezube ◽  
L. Gandhi ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Hsp90 Inhibitor ◽  
Dose Escalation Study

A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 2529-2529 ◽  
Author(s):  
J. W. Goldman ◽  
R. N. Raju ◽  
G. A. Gordon ◽  
V. M. Vukovic ◽  
R. Bradley ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Hsp90 Inhibitor ◽  
Dose Escalation Study

A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 14613-14613 ◽  
Author(s):  
J. C. Bryson ◽  
J. R. Infante ◽  
R. K. Ramanathan ◽  
S. F. Jones ◽  
D. D. Von Hoff ◽  
...  
Keyword(s):  
Dose Escalation ◽  
Phase 1 ◽  
Hsp90 Inhibitor ◽  
Dose Escalation Study

A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3051-3051 ◽  
Author(s):  
D. C. Cho ◽  
E. I. Heath ◽  
J. M. Cleary ◽  
E. L. Kwak ◽  
L. Gandhi ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Hsp90 Inhibitor ◽  
Dose Escalation Study
Sign in / Sign up

Export Citation Format

Share Document